Richard Vaillancourt

Professor with expertise in pharmacology and toxicology, Richard Vaillancourt, PhD, serves as an Associate Professor at the University of Arizona. His academic journey is marked by a profound commitment to understanding the intricate mechanisms of cancer biology, particularly within the realm of the tumor microenvironment. Dr. Vaillancourt's research is pivotal in elucidating the complex interactions that govern cancer cell growth, with a specialized focus on HER2+ breast cancer. Dr. Vaillancourt is an integral part of the Cancer Biology Graduate Interdisciplinary Program, where he delves into the nuanced role of the tumor microenvironment in cancer progression. His research is centered on the metabolic byproduct lactate and its receptor, GPR81, exploring their significant impact on the proliferation of cancer cells. Through his work, he aims to uncover novel therapeutic targets that could potentially disrupt the growth of cancer cells in HER2+ breast cancer, offering new avenues for treatment. With a keen interest in the intersection of cancer biology and pharmacology, Dr. Vaillancourt's contributions extend beyond the laboratory. He is actively involved in mentoring the next generation of scientists, fostering a collaborative and innovative research environment. His dedication to advancing the understanding of cancer biology is reflected in his numerous publications and presentations at national and international conferences. Dr. Vaillancourt's research not only enhances the scientific community's comprehension of cancer dynamics but also holds promise for translating these findings into clinical applications. His work continues to inspire and drive forward the field of cancer research, with the ultimate goal of improving patient outcomes and advancing therapeutic strategies.